Tim Sweeney is the co-founder and CEO of Inflammatix, a Sunnyvale molecular diagnostics company that reads the immune system instead of hunting for pathogens. A surgeon-turned-entrepreneur with an MD/PhD from Duke and a biomedical informatics background from Stanford, he built TriVerity, an FDA-cleared rapid blood test that measures 29 immune-response genes and uses machine learning to score the likelihood of bacterial infection, viral infection, and severe illness. He has raised more than $200 million to bring precision medicine to sepsis and critical care.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Samuel Rodriques is a physicist-turned-bioengineer and co-founder and CEO of Edison Scientific, the AI-driven scientific discovery company behind Kosmos - an AI scientist that reportedly condenses six months of PhD-level research into a single day. A MIT PhD and Hertz Fellow who invented implosion fabrication and pioneered spatial transcriptomics, Rodriques left the Francis Crick Institute to co-found FutureHouse (funded by Eric Schmidt) in 2023, then spun it into for-profit Edison Scientific, which raised a $70M seed round at a $250M valuation in December 2025. Named to Time 100 AI in 2025, he is on a mission to cure all diseases by mid-century through AI-accelerated science.